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Background: FABP1 has been reported to possess strong antioxidant properties. Upon successful transfection of
the Chang cell line, which has undetectable FABP1 mRNA levels, with human FABP1 cDNA, the Chang cells
were shown to express FABP1. Using the transfected and control (normal) Chang cells and subjecting them to
oxidative stress, transfected cells were reported to be associated with enhanced cell viability. This study extends
those observations by investigating the effect of FABP1 on acetaminophen (AAP)-induced hepatotoxicity. We
hypothesized that presence of FABP1 would enhance cell viability compared to control cells (vector transfected
cells).
Methods: Following AAP treatment of Chang FABP1 transfected and control cells, cell viability, oxidative stress, and
apoptosis were evaluated using lactate dehydrogenase (LDH) release, the fluorescent probe DCF, and Bax
expression, respectively.
Results: FABP1 cDNA transfected cells showed greater resistance against AAP toxicity than vector transfected cells.
Significantly lower LDH levels (p < 0.05) were observed as were lower DCF fluorescence intensity (p < 0.05) in
FABP1 cDNA transfected cells compared to vector transfected cells. FABP1 expression also attenuated the
expression of Bax following AAP induced toxicity.
Conclusion: FABP1 attenuated AAP-induced toxicity and may be considered a cytoprotective agent in this in vitro
model of drug induced oxidative stress.
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Fatty acid binding protein (FABP) was first discovered in
1969 by Levi et al. [1]. Liver fatty acid binding protein
(FABP1), named after the tissue in which it was first iden-
tified, is approximately a 14–15 kDa protein mainly
present in the cytoplasm of hepatocytes but expressed in
many other tissues [2,3]. FABP1’s main function is
thought to be the intracellular transport of lipophilic sub-
strates such as long chain fatty acids. FABP1 also interacts
indirectly with the peroxisome proliferator-activated re-
ceptor alpha (PPARα), which is a key regulator of lipid
homeostasis in hepatocytes and a target for fatty acids
and hypolipidemic drugs, by transporting PPARα agonists* Correspondence: burczyn@cc.umanitoba.ca
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reproduction in any medium, provided the orto its site. Thus, FABP1 acts as a cytosolic gateway by
directing PPAR ligands to the nucleus [4].
A new antioxidant property of FABP1 has recently
been uncovered [5,6]. In its primary structure FABP1
contains seven methionine and one-cysteine amino
acids. These groups are regarded as cellular scavengers
of activated xenobiotics and are involved in trapping of
free radicals [7]. Thus, in this study we used an acet-
aminophen induced toxicity model in cultured cells to
assess the antioxidant function of FABP1.
Acetaminophen (AAP), 4-hydroxyacetanilide, is a widely
utilized drug known for its analgesic and antipyretic
properties. When used at therapeutic levels it is safe,
however, an acute or cumulative overdose can cause se-
vere liver injury with the potential of liver failure [8]. At
therapeutic doses, AAP is primarily detoxified by glucur-
onidation and sulfation with a small fraction metabolized
by cytochrome P-450-dependent mixed function oxidasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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mine (NAPQ1) metabolite [9]. The metabolite reacts
with glutathione (GSH) spontaneously or is catalyzed
by glutathione-S-transferases to form a GSH-adduct
which is mainly excreted into bile through Mrp2 with-
out significant toxicity [10]. After an AAP overdose,
however, glucuronidation and sulfation are insufficient
to detoxify AAP. A large fraction of the drug becomes
available for metabolism by cytochrome P450, leading
to a rapid depletion of hepatic GSH levels. Once GSH
is exhausted, any remaining NAPQI formed will react
with alternative targets, in particular cellular proteins
[11]. In addition to NAPQI, other cellular effects of
AAP toxicity further exacerbates cellular oxidative
stress which in turn contributes to the cell injury
process [12].
The present study investigates the hepatoprotective
effect of FABP1 in acetaminophen-induced toxicity using
the Chang cell line. Chang cells were originally thought
to be derived from normal liver tissue, but subsequently
found to have been established via HeLa cell contamin-
ation. The rationale for using this cell line, however,
rests in the fact that these cells were shown to be devoid
FABP1 [5], yet have the metabolic enzymes responsible
for metabolizing AAP to the NAPQ1 reactive species
[12]. Thus, it is an ideal cell line to study the biological
and bioprotective effects of FABP1.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), sodium
pyruvate, penicillin, streptomycin, Geneticin (G-418) and
sodium pyruvate were purchased from GIBCO/BRL (Life
Technology, Burlington, ON). Acetaminophen, calf serum
and β- nicotinamide adenine di-nucleotide, reduced form
of β-NADH, were purchased from Sigma (Sigma, Co., St.
Louis, MO). The cellular toxicity assay kit (WST-1) was
purchased from Roche (Roche Diagonstics GmbH, Mann-
heim, Germany), anti-Bax (N-20) monoclonal antibody
was from Santa Cruz Biotechnology, Inc., horseradish
peroxidase conjugated anti-mouse lgG (sheep) was from
Amersham biosciences, anti-rabbit lgG horseradish per-
oxidise linked whole antibody was from GE healthcare,
and rainbow molecular weight marker was purchased
from Invitrogen. FABP1 polyclonal antibody was gener-
ated in our laboratory.
Methods
Cell cultures
Chang cells were obtained from American Type Cul-
ture Collection (Manassas, VA, USA). Vector and
FABP1 cDNA transfected Chang cells [5] were grown
in DMEM supplemented with 100 U of penicillin/ml,
100 μg streptomycin/ml and 10% calf serum, in ahumidified 37°C incubator with an atmosphere of
95% air and 5% CO2. The transfected Chang cells
were maintained in the presence of G418 (Geneticin)
at a concentration of 200 mg/L.
Cells were seeded at a density of 1 × 104 cells/well (for
WST-1 and DCF assay, 96-well plates), 1 × 105 cells/well
(for LDH assay, 6-well plates) and 1 × 106 cells/well (for
Western blot, 60 mm dishes) in DMEM medium and in-
cubated overnight for adherence. The next day cell cul-
tures were washed once with warm phosphate-buffered
saline (PBS) and incubated with AAP for 3, 6, 12, and
24 hrs at 37°C in a humidified incubator in an atmos-
phere of 95% air and 5% CO2. At the end of the incuba-
tion period, cells were prepared for the various assays
described below.Cell viability
The cell proliferation reagent WST-1 is based on the
metabolic activity of viable cells. WST-1 (10 μl/well) was
added to cells that had already been treated with AAP
(0 mM, 0.5 mM, 1 mM, 5 mM, 10 mM, and 20 mM) for
3, 6, 12, and 24 hrs, followed by 3 hrs incubation with
WST-1. Cell viability was measured using a spectra Max
190 (Molecular Devices) plate reader at 440 nm.
The release of lactate dehydrogenase (LDH) from cells
during the incubation period with AAP was used to deter-
mine cell damage. Briefly, after treatment with 10 mM
AAP for 3, 6, 12 and 24 hrs, LDH activity in the super-
natant was determined as follows: a 10% (v/v) 2.5 mM
NADH was mixed with 10% (v/v) 25 mM pyruvate in a
Tris-KCl buffer (50:150 mM, PH= 7.4) on the day of the
assay and equilibrated to 25°C in a water bath prior to use.
Aliquots (50 μl) of the culture supernatants (containing
LDH) were added to a quartz cuvette that contained
1000 μl substrate solution and then measured in UV-
visible recording spectrometer (UV-160). Change in
absorbance at 340 nm was directly proportional to LDH
activity in the supernatant samples.DCF measurements
Fluorescence intensity of DCF from reactive oxygen spe-
cies (ROS) formed in cell cultures was assessed using a
Wallac 1420 multilable counter (Perkin Elmer). A
10 mM (4.87 mg/ml) stock solution of 2,7- dichlorofluor-
escein diacetate (H2DCFDA) was prepared daily in etha-
nol and stored at – 20°C until required and diluted to
1 mM with PBS prior to each study. Following incubation
with AAP, cells were washed twice with Ca++/Mg++-PBS
and incubated with 100 μM 2,7-dichlorofluorescin diace-
tate (DCFH2-DA) at room temperature in the dark for
30 min. Mean of fluorescence intensity was calculated
from 4-wells of control and drug-treated cells from six
separate experiments.
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After AAP treatment, protein extracts were prepared
from cell cultures using RIPA Buffer (50 mM Tris–HCl
pH 7.4, 150 mM NaCl, 1 mM PMSF, 1 mM EDTA,
5 μg/ml Aprotinin, 5 μg/mL Leupeptin, 1% Triton x-
100, 1% Sodium deoxycholate, 0.1% SDS). Briefly, cell
pellets (1 × 106) were washed once with ice-cold PBS
and incubated with 1 ml RIPA buffer on ice for 20 min,
vortexing 2–3 times. The lysate was centrifuged for
5 min at 4°C at 20,000 g in microfuge tubes. Superna-
tants were transferred to clean tubes. Protein concentra-
tion was measured using the BCA Protein Assay.
Samples were stored at −80°C until required. The optical
density values of each target protein band were deter-
mined using NIH Imaging software.
Statistical analyses
Statistical analyses of the treatment groups were carried
out by t test (unpaired) where 2 groups were compared
while a two-way ANOVA was used for multiple compar-




Cytotoxicity induced by AAP in vector and FABP1 cDNA
transfected cells using the cell proliferation reagent WST-
1 is shown in Figure 1. AAP induced a dose-dependent
cytotoxicity in both vector and FABP1 cDNA transfected
cells. The FABP1 cDNA transfected cells, however, showed
lower cytotoxicity then vector-transfected cells following
3 hrs of AAP treatment. Drug exposure times of 6 hrs,
12 hrs and 24 hrs, were also investigated with results simi-
lar to those shown for 3 hrs (data not shown). VectorFigure 1 Cytotoxicity of vector and FABP1 transfected cells
exposed to various AAP concentrations for 3 hrs as measured
by WST-1. The two groups of cells were treated with 0, 0.5, 1, 5, 10,
20 mM concentrations of AAP for 3 hrs. Data show mean ± SE; n = 6;
**p < 0.01 (for 20 mM AAP), ***p < 0.001 (for 0.5 mM, 1.0 mM, 5 mM,
and 10 mM AAP) between FABP1 cDNA and vector transfected cells
during the same time period.transfected Chang cells showed a 15%, 19%, 23%, 27%,
and 37% decrease in viability at concentrations of
0.5 mM, 1 mM, 5 mM, 10 mM, and 20 mM AAP, re-
spectively; while cell viability in the FABP1 cDNA trans-
fected cells showed a 2%, 6%, 14%, 17%, and 23%
reduction at the same concentrations, suggesting that
FABP1 might have a cytoprotective role against AAP in-
duced cytotoxicity. Comparing the FABP1 cDNA trans-
fected cells to the vector transfected cells at AAP
concentrations of 0.5 mM, 1.0 mM, 5 mM, and 10 mM
showed highly significant differences at the p < 0.001
level, while an AAP concentration of 20 mM was signifi-
cant at the p < 0.01 level. There was no statistical differ-
ence between the two cell types in the absence of AAP.
ROS levels
Oxidative stress is one of major causes of AAP induced
cell injury. As a measure of reactive oxygen species
(ROS) we used the ROS-sensitive probe 2,7-dichloro-
fluorescein diacetate (H2DCFDA) to monitor AAP in-
duced cellular oxidative stress. Figure 2 shows DCF
fluorescence results from experiments where vector and
FABP1 cDNA transfected cells were incubated for 3 hrs
with 1 mM, 5 mM, and 10 mM AAP. Cells incubated
with AAP for 6 hrs showed similar results (data not
shown). AAP induced a dose-dependent oxidative stress
in both vector-transfected cells and FABP1 cDNA trans-
fected cells. DCF fluorescence intensity in FABP1 cDNA
transfected cells was, however, significantly reduced
(p < 0.05) compared to vector transfected cells at each
AAP concentration (Figure 2). Compared to vector
transfected cells, DCF fluorescence intensity of FABP1
cDNA transfected cells decreased by 35% ± 5% at 1 mMFigure 2 DCF fluorescence intensity of vector and FABP1 cDNA
transfected cells in the presence of 1 mM, 5 mM, 10 mM AAP
for 3 hours. Cells were cultured in black 96-well plates. After AAP
treatment H2DCFDA (1 mM) was loaded into wells for 30 minutes.
Cellular fluorescence in each well was measured and immediately
recorded. Date represent mean ± SEM; n = 6; ***p < 0.001 between
FABP1 cDNA transfected and vector transfected cells during the
same time period.
Figure 4 Expressions of Bax in FABP1 cDNA and vector
transfected cells after being treated with 10 mM AAP for 0, 3,
6, 12, and 24 hrs. β-Actin served as the loading control (n = 6,
mean ± SEM, *p < 0.05).
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46% ± 5% at 10 mM AAP treatment (p < 0.001).
LDH levels
The protective effect of FABP1 in AAP induced liver
failure was assessed by detecting cellular LDH release.
Release of LDH into culture supernatant correlates with
reduced cell membrane integrity and cell viability. As
shown in Figure 3, a statistical decrease (p < 0.01) in
supernatant LDH activity was found in FABP1 cDNA
transfected cells only after 12 and 24 hrs of 10 mM AAP
treatment compared with vector transfected cells. No
statistical difference was observed in the 3 hrs AAP
treatment group compared to the control group, sug-
gesting that LDH release may be a late event in AAP in-
duced cell injury that is preventable by FABP1.
Bax and FABP1 levels
Western blot analysis was used to detect the expression
of the pro-apoptotic protein Bax in cells following
0 hrs, 3 hrs, 6 hrs, 12 hrs, and 24 hrs incubation with
10 mM AAP. FABP1 cDNA transfected cells had lower
levels of Bax then vector transfected cells at each time
period (p < 0.05; see Figure 4). Bax level in the vector-
transfected cells started to increase following 3 hrs in-
cubation with AAP and peaked at 12 hrs. Bax level in
the FABP1 cDNA transfected cells remained constant
until 12 hrs when the Bax level statistically increased
from the 6 hrs level (p < 0.05).
To verify the role of FABP1 in AAP induced toxicity,
FABP1 expression was analysed in each group. As ex-
pected there was no FABP1 present in the vector-
transfected group while the FABP1 cDNA transfectedFigure 3 LDH release from FABP1 cDNA and vector transfected
cells subjected to 10 mM AAP treatment for 3 hrs, 6 hrs, 12 hrs,
and 24 hrs. Negative control experiments were performed by
incubating cells with no serum DMEM for 24 hrs. LDH absorbance
was measured at 340 nm and expressed as the rate of absorbance
change per minute. Data represent mean ± SEM (n = 4), **p < 0.01
LDH activity of FABP1 cDNA transfected cells compared with vector
transfected cells during the same time period.showed presence of the protein (Figure 5). The FABP1
level decreased over time in the AAP treated group. The
slope of the regression line was significantly different
from zero (p < 0.05), suggesting that either the AAP tox-
icity damaged transcriptional/translational events or
cells were made leaky such that the FABP1 was able to
efflux from cells.
Discussion
Acetaminophen (AAP) is an effective over the counter
medication for relief of minor pain and fever. A small
fraction of the AAP dose is metabolized by CYP 2E1 to a
highly reactive N-acetyl-p-benzoquinone imine (NAPQI)
metabolite. This metabolite is inactivated by glutathione
or GSH within the liver. However, if the concentration of
NAPQI is high, liver damage can occur. In severe cases
liver failure and death occur. Despite its widespread use,Figure 5 Expressions of FABP1 in FABP1 cDNA transfected cells
after being treated with 10 mM AAP for 0, 3, 6, 12, and 24 hrs
(n = 6, mean ± SEM).
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ing investigated. Many studies have reported impaired
mitochondrial respiration [13,14], depletion of hepatocel-
lular ATP levels [15,16], opening of the mitochondrial
membrane permeability transition pore [17], and in-
creased levels of glutathione disulfide (GSSG) or the ratio
of GSSG:GSH, suggesting the involvement of an oxidant
stress following AAP overdose [15,18]. In response to
high levels of ROS the nascent hepatocyte antioxidants
may not provide sufficient capacity to inactivate them,
other antioxidant defence systems are expected to take
effect. FABP1, with its high affinity and capacity to bind
lipophilic oxidative products [19,20], is a likely candidate
for further protecting hepatocytes from ROS.
Our previous work showed that Chang cells were de-
void of FABP1. Transfecting the Chang cell line with
FABP1 cDNA gave us an opportunity to study this pro-
tein in different models of oxidative stress. Using a hyp-
oxia/reoxygenation as well as a H2O2 induced oxidative
stress models [5], we reported that while FABP1 cDNA
transfected cells had the same complement of intracellu-
lar antioxidant enzymes as the vector transfected cell
line, FABP1 cDNA transfected cells were associated with
much less ROS levels, suggesting that FABP1 is some-
how involved in inactivating free radicals. Yan et al. [21]
investigated the mechanism for the antioxidant protect-
ive function of FABP1. Rat FABP1 is known to have
seven methionine groups in positions 1, 19, 22, 74, 85,
91, and 113, as well as one cysteine group in position 69.
Methionine and cysteine are known to react with ROS.
Using a recombinant form of rat FABP1 that was cul-
tured in E. coli, isolated and purified, the group showed
that indeed the methionine groups of FABP1 were asso-
ciated with reactive oxygen as assessed by MALDI-TOF.
Moreover, FABP1 was shown to react with free radicals
in both hydrophilic and lipophilic domains of the cell.
Using AAPH as a hydrophilic free radical generator the
group determined that methionine 1, 19, 22, 91, and 113
were oxidized. In the lipophilic environment, using
AMVN as the lipophilic free radical generator, methio-
nine 1, 19, 22, and 113 were only reactive. Methionine
74 and 85 were unreactive in both systems suggesting
that these groups may be buried deep within the binding
site of FABP1 while the other reactive groups are surface
exposed. Interestingly, methionine 91 did not react with
any free radicals in the lipophilic domain. This suggested
that FABP1 might orientate itself to the membrane
allowing other methionine groups access to react with
free radicals at the membrane surface. FABP interaction
with membrane surfaces has been suggested to occur
with FABP2 (intestinal fatty acid binding protein) but
not with FABP1 [22].
In this study we investigated the role of FABP1 in
drug-induced liver damage. The data show a rapid onsetof an intracellular oxidative stress as early as 3 hrs in
cultured cells using 2,7-dichlorofluorescein diacetate
(H2DCFDA) as a marker of intracellular free radical
levels. There was a dose-dependent increase in released
ROS induced by AAP with DCF fluorescence intensities
being significantly lower in FABP1 cDNA transfected
cells compared to the vector transfected cells (Figure 2).
AAP induced oxidative stress was studied by other
groups such as Bajt et al. [23] who showed that a greater
than 10 fold increase in ROS levels between 3.5 and
12.5 hrs resulted following 5 mM AAP treatment in cul-
tured murine hepatocytes. Pretreatment of hepatocytes
with 20 mM N-acetylcysteine was shown to enhance cel-
lular glutathione content and suppressed the AAP-
induced decrease in cell viability. Bajt concluded that
AAP-induced oxidant stress precedes cell necrosis and
the oxidant stress is involved in the propagation of cell
injury.
The effect of FABP1 on AAP-induced cell damage was
assessed using the WST-1 assay in our study, which de-
pends on mitochondrial respiration [24,25]. Results from
this assay indicated a substantial functional deterioration
of hepatocytes following AAP treatment. Similar to the
DCF assay, results showed that the cytotoxicity induced
by AAP was dose-dependent and statistical differences
were observed between FABP1 cDNA and vector trans-
fected cells following 3 hrs drug treatment (Figure 1).
Thus, FABP1 protects cellular mitochondrial function in
some way. One possibility is by inactivating cytosolic
free radicals. These reactive species are not able to inter-
act with the mitochondrial membrane, thus, preserving
cellular function. AAP also caused a progressive release
of LDH into the culture media, showing cellular damage.
The presence of FABP1 attenuated this increase but only
at the latter stages of AAP induced cell injury since
LDH release only became statistically significant after
12 hrs of treatment. As well as being present in the cyto-
sol, FABP1 is also present in the mitochondria. It is
likely that FABP1 plays an early protective role in AAP
induced mitochondrial impairment through scavenging
free radicals within the mitochondria itself as well as in
the cytosol.
The mechanism of AAP-induced cell death is not
completely understood. Of the events leading to apop-
totic and/or necrotic cell death, Bax seems to be central
for the mitochondrial-dependent mechanisms. Bax is a
pro-apoptotic Bcl-2 family member that plays a pivotal
role in the formation of the mitochondrial permeability
pore. Higher levels of Bax are associated with changes in
the outer membrane permeability, which are responsible
for changes in the inner mitochondrial membrane that
leads to disruption in cell function (e.g., membrane po-
tential, cell swelling, leakage). Deletion of Bax has been
shown to be associated with dramatic reduction in
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Bax may modulate necrosis through mechanisms that
are distinct from apoptosis [26,27]. In our study, de-
creased Bax levels were seen in the AAP treated FABP1
cDNA transfected group at all time points (Figure 4). In
the vector-transfected groups the Bax level started to
statistically increase at 3 hrs and peaked at 12 hrs. This
was not seen in the FABP1 cDNA transfected cells. In
the FABP1 cDNA transfected group the Bax level in-
creased only after 12 hr incubation with AAP. Thus,
FABP1 shows a higher protective ability at the early time
points (3 and 6 hrs) by preventing the increase in Bax
level. At the late time points (12 and 24 hrs), Bax level
in the FABP1 cDNA transfected group was lower than
in the vector-transfected group but still higher than at
the 6 hrs FABP1 cDNA transfected group. FABP1 levels,
however, were also declining during the late time points.
A rationale explanation for the declining FABP1 levels is
not apparent. Studies aimed at assessing the time course
of FABP1 mRNA activity would be necessary to explain
the decrease in FABP1 levels. Presence of necrosis may
be a possibility that leads to the release of FABP1.
Nevertheless a strong correlation exists between FABP1
and Bax levels, showing that FABP1 prevents cell death
through a reduction in Bax activity. Although our work
cannot discern whether the higher (or lower) levels of
Bax is associated with Bax translocation to the mito-
chondria, it is reasonable to speculate that the increased
levels would lead to increased translocation. Bajt had
earlier reported that following 300 mg/Kg intraperito-
neal AAP injection to C57BL/6 mice, Bax translocation
from the cytosol to mitochondria occurs as early as 1 hr
[28]. Thus, FABP1 likely protects cells against AAP hep-
atotoxicity during the early time periods of hepatocyte
injury.
LDH release is indicative of cell death. Membranes be-
come leaky through a variety of processes including that
of oxidative damage. Since release of LDH in our study
reached statistical significance only after 12 hrs of AAP
treatment, this showed that although earlier time points
were associated increased Bax level, later time points in-
volved necrosis. As stated above apoptosis and necrosis
are not completely independent processes [29]. These
two processes share a common mitochondrial perme-
ability transition (MPT) pathway. When the MPT occurs
abruptly, ATPase becomes activated which depletes ATP
levels leading to membrane rupture and oncotic necro-
sis. However, the ATP level can remain constant (base-
line condition) when the MPT proceeds relatively slowly
or the ATPase is inhibited by glycolysis or oligomycin.
Under these conditions, necrosis can be blocked and
apoptosis occurs. At any time, ATP depletion can super-
vene to cause secondary necrosis. A new term, necra-
poptosis has been introduced to describe a deathprocess that begins with death signals or toxic stress,
proceeds by shared pathways, but results in either cell
lysis (oncotic necrosis) or programmed cellular resorp-
tion (apoptosis) depending on other factors, such as
ATP [29]. In our study FABP1 attenuated the increased
LDH release. It is not clear on the exact mechanism (dir-
ect or indirect) for the FABP1’s hepatoprotective effect
but we speculate that it may in part be likely due to its
antioxidant role.Conclusions
In summary, this study demonstrated that FABP1 plays
an important protective function in AAP induced tox-
icity. The exact mechanism, however, is yet to be eluci-
dated. Since oxidative stress is a major mitigating factor
for cellular dysfunction in many diseases or drug in-
duced complications, it seems logical that FABP1 levels
could be increased to help combat the released ROS
levels.
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